Nina Helbekkmo
Yngvar Nilssen,
Odd Terje Brustugun,
Lars Fjellbirkeland,
Bjørn Henning Grønberg,
Per Magnus Haram,
Nina Helbekkmo
m.fl.:
Small Cell Lung Cancer in Norway: Patterns of Care by Health Region and Survival Trends
Henrik Horndalsveen,
Tine Norman Alver,
Astrid Marie Dalsgaard,
LOTTE VICTORIA ROGG,
Nina Helbekkmo,
Bjørn Henning Grønberg
m.fl.:
Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT-1 trial
Tarje Onsøien Halvorsen,
Kristin Stokke,
Kristin Toftaker Killingberg,
Sunil Xavier Raj,
Sveinung Sørhaug,
Odd Terje Brustugun
m.fl.:
Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC
Acta Oncologica 2020 DOI
Steinar Solberg,
Yngvar Nilssen,
Odd Terje Brustugun,
Tom Kristian Grimsrud,
Per Magnus Haram,
Nina Helbekkmo
m.fl.:
Increase in curative treatment and survival of lung cancer in Norway 2001-2016
Odd Terje Brustugun,
Bjørn Henning Grønberg,
Lars Fjellbirkeland,
Nina Helbekkmo,
Marianne Aanerud,
Tom Kristian Grimsrud
m.fl.:
Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016
Jan Norum,
Margaret Aarag Antonsen,
Terje Tollåli,
Khalid Al-Shibli,
Gry Andersen,
Kristin-Helene Svanqvist
m.fl.:
Pembrolizumab as second-line therapy
in non-small cell lung cancer in
northern Norway: budget impact and
expected gain — a model-based analysis
Øystein Fløtten,
Bjørn Henning Grønberg,
Stein Harald Sundstrøm,
Nina Helbekkmo,
Roy M. Bremnes,
Christian von Plessen
:
Oral versus intravenous vinorelbine in advanced NSCLC - a retrospective comparison
Cancer Treatment and Research Communications 2016 DOI
Hans Henrik Strøm,
Roy M. Bremnes,
Stein Harald Sundstrøm,
Nina Helbekkmo,
Ulf Aasebø
:
How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced NoneSmall Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial
Hans Henrik Strøm,
Roy M. Bremnes,
Stein Harald Sundstrøm,
Nina Helbekkmo,
Ulf Aasebø
:
Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: A subset analysis from a randomized clinical phase III trial
Hans Henrik Strøm,
Roy M. Bremnes,
Stein Harald Sundstrøm,
Nina Helbekkmo,
Øystein Fløtten,
Ulf Aasebø
:
Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group
Tom Dønnem,
Bente Ervik,
Kathrine Magnussen,
Sigve Andersen,
Doris Ruth Pastow,
Sissel Andreassen
m.fl.:
Bridging the distance: a prospective tele-oncology study in Northern Norway
Supportive Care in Cancer 2012 DOI
Nina Helbekkmo,
Hans H. Strøm,
Hans Henrik Strøm,
Stein Sundström,
Stein H. Sundstrøm,
Ulf Aasebö
m.fl.:
Chemotherapy and quality of life in NSCLC PS 2 patients
Acta Oncologica 2009 DOI
Nina Helbekkmo,
Ulf Aasebø,
Stein Sundstrøm,
Christian Von Plessen,
Paal Brunsvig,
Roy M. Bremnes
:
Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy
Lung Cancer 2008 DOI
Nina Helbekkmo,
Stein Sundström,
Stein Sundstrøm,
Ulf Aasebø,
Paal Brunsvig,
Christian Von Plessen
m.fl.:
Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity
British Journal of Cancer 2007 DOI
Anders Vik,
Nina Helbekkmo,
Roy M. Bremnes
:
Låggradig non-Hodgkins lymfom i Nord-Noreg
Tidsskrift for Den norske legeforening 2002
Roy M. Bremnes,
Anders Vik,
Nina Helbekkmo
:
Low-grade non-Hodgkin's lymphoma in northern Norway: treatment, outcome, and prognostic factors
Anticancer Research 1998
Bjørn Henning Grønberg,
Kristin Toftaker Killingberg,
Øystein Fløtten,
Maria Moksnes Bjaanæs,
Tesfaye Madebo,
Tine Schytte
m.fl.:
Final survival data from a randomized phase II trial comparing high-dose with standard-dose twice-daily (BID) thoracic radiotherapy (TRT) in limited stage small-cell lung cancer (LS SCLC)
Hans Henrik Strøm,
Stefan Sundström,
Nina Helbekkmo,
Roy M. Bremnes,
U Aasebo
:
CONCOMITANT CHEMORADIATION GIVES SIGNIFICANT SURVIVAL AND HRQOL BENEFITS IN PATIENTS WITH LOCALLY ADVANCED STAGE III NON SMALL CELL LUNG CANCER (NSCLC) NOT ELIGIBLE FOR RADICAL TREATMENT: A RANDOMIZED TRIAL BY THE NORWEGIAN LUNG CANCER STUDY GROUP
Annals of Oncology 2012
Nina Helbekkmo
:
Chemotherapy for PS 2 patients, the VING experience
2008
Nina Helbekkmo,
Ulf Aasebø,
Ulf Aasebö,
Stein H. Sundstrøm,
Stein Sundström,
Christian Von Plessen
m.fl.:
Outcome of patients with WHO performance status 2 in a randomized trial comparing vinorelbine/carboplatin with gemcitabine/carboplatin in advanced NSCLC
Journal of Thoracic Oncology 2007
Nina Helbekkmo
:
Ikke-småcellet lungekreft, PS 2 pasienten: symptombyrde, intervensjon og effekt av behandling. Skal disse pasientene ha rutinemessig tumorrettet behandling? Erfaring og resultater fra VING-studien
2007
Nina Helbekkmo,
Stein H. Sundstrøm,
Ulf Aasebø,
Christian von Plessen,
Paal Brunsvig,
Roy M. Bremnes
:
A randomized comparison of carboplatin/vinorelbine versus carboplatin/gemcitabine in advanced non-small cell lung cancer (NSCLC)
Journal of Clinical Oncology 2006
De 50 siste resultatene fra Cristin vises på siden. Se alle arbeider i Cristin her →